Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
Pacira Pharmaceuticals, Inc. is an acute care specialty pharmaceutical company founded in March, 2007 through the acquisition of the former skyepharma
PLC injectable business, for which an experienced management team was assembled to address the needs of the acute care market. The company's most adv...
U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease
...d-release, once-daily tablet formulation that
PLC's (LSE: SKP) patented GEOMATRIX(TM) technology... bothered
enough to stop taking Requip XL.
Using its proprietary drug delivery technologies, skyepharma
new formulations of existing products to ...
Once Daily, Extended-Release Ropinirole Improves Parkinson's
Symptoms in Patients not Optimally Controlled With Levodopa
ropinirole for treating Parkinson's disease using skyepharma
proprietary GeoMatrix technology.
About th...ctor about any side effects they
develops pharmaceutical products benefiting from
Sciele Pharma Announces Successful Completion of New Sular
Formulation Clinical Trial Program
...lity of life, and implementing its business platform - an
Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity,
Using its proprietary drug delivery technologies, SkyePharma
develops new formulations of known molecules to provide a clinical
advantage and li...
SkyePharma and Sciele Pharma Announce Successful Completion of New
Sular Formulation Clinical Trial Programme
LONDON, UK and ATLANTA, US, May 14, 2007 - skyepharma
(LSE:SKP; NASDAQ:SKYE) and Sciele Pharma. Inc....tered trademark of Sciele Pharma, Inc.
Using its proprietary drug delivery technolo... related
to SkyePharma's ability to manage growth. skyepharma
obligation to revise or update any s...
Critical Therapeutics Announces the Publication of Data for ZyfloCR
(Zileuton) Extended-Release Tablets in the Journal of Asthma
...ered trademark of Critical Therapeutics,
ZYFLO CR(TM) is a trademark of Critical Therapeutics, Inc.
Geomatrix(R) is a registered trademark of skyepharma
Critical Therapeutics, Inc.
Linda S. Lennox, 781-402-5708
Vice President, Investor & Media Relations
(Date:5/22/2015)... 22, 2015 According to a ... (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by ... Utilities, Consumer and Home) - Global Forecast to 2020", ... $2.77 Billion in 2015 to $6.19 Billion by 2020, ... 79 market data Tables and 43 Figures spread ...
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market" report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ... Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2